Skip to main content
. 2017 Sep 19;5:71. doi: 10.1186/s40425-017-0277-7

Fig. 1.

Fig. 1

Study design and patient disposition. a Two patients were excluded at screening because of inadequate renal function, and one because of bowel obstruction. b Cohorts C–E initiated after completion of cohort A and B comparison phase. c Enadenotucirev (EnAd) administration days also counted as assessment visits (i.e. cohort A: day 1; cohort B: days 1, 3, and 5)